A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report

Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response...

Descripción completa

Detalles Bibliográficos
Autores principales: De Divitiis, Chiara, von Arx, Claudia, Carbone, Roberto, Tatangelo, Fabiana, Di Girolamo, Elena, Romano, Giovanni Maria, Ottaiano, Alessandro, de Lutio di Castelguidone, Elisabetta, Iaffaioli, Rosario Vincenzo, Tafuto, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386800/
https://www.ncbi.nlm.nih.gov/pubmed/25878507
http://dx.doi.org/10.2147/OTT.S71025
_version_ 1782365211917811712
author De Divitiis, Chiara
von Arx, Claudia
Carbone, Roberto
Tatangelo, Fabiana
Di Girolamo, Elena
Romano, Giovanni Maria
Ottaiano, Alessandro
de Lutio di Castelguidone, Elisabetta
Iaffaioli, Rosario Vincenzo
Tafuto, Salvatore
author_facet De Divitiis, Chiara
von Arx, Claudia
Carbone, Roberto
Tatangelo, Fabiana
Di Girolamo, Elena
Romano, Giovanni Maria
Ottaiano, Alessandro
de Lutio di Castelguidone, Elisabetta
Iaffaioli, Rosario Vincenzo
Tafuto, Salvatore
author_sort De Divitiis, Chiara
collection PubMed
description Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.
format Online
Article
Text
id pubmed-4386800
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43868002015-04-15 A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report De Divitiis, Chiara von Arx, Claudia Carbone, Roberto Tatangelo, Fabiana Di Girolamo, Elena Romano, Giovanni Maria Ottaiano, Alessandro de Lutio di Castelguidone, Elisabetta Iaffaioli, Rosario Vincenzo Tafuto, Salvatore Onco Targets Ther Case Report Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs. Dove Medical Press 2015-03-31 /pmc/articles/PMC4386800/ /pubmed/25878507 http://dx.doi.org/10.2147/OTT.S71025 Text en © 2015 De Divitiis et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
De Divitiis, Chiara
von Arx, Claudia
Carbone, Roberto
Tatangelo, Fabiana
Di Girolamo, Elena
Romano, Giovanni Maria
Ottaiano, Alessandro
de Lutio di Castelguidone, Elisabetta
Iaffaioli, Rosario Vincenzo
Tafuto, Salvatore
A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
title A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
title_full A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
title_fullStr A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
title_full_unstemmed A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
title_short A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
title_sort clinical and radiological objective tumor response with somatostatin analogs (ssa) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386800/
https://www.ncbi.nlm.nih.gov/pubmed/25878507
http://dx.doi.org/10.2147/OTT.S71025
work_keys_str_mv AT dedivitiischiara aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT vonarxclaudia aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT carboneroberto aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT tatangelofabiana aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT digirolamoelena aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT romanogiovannimaria aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT ottaianoalessandro aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT delutiodicastelguidoneelisabetta aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT iaffaiolirosariovincenzo aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT tafutosalvatore aclinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT dedivitiischiara clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT vonarxclaudia clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT carboneroberto clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT tatangelofabiana clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT digirolamoelena clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT romanogiovannimaria clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT ottaianoalessandro clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT delutiodicastelguidoneelisabetta clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT iaffaiolirosariovincenzo clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport
AT tafutosalvatore clinicalandradiologicalobjectivetumorresponsewithsomatostatinanalogsssainwelldifferentiatedneuroendocrinemetastatictumoroftheileumacasereport

Ejemplares similares